Transcription-modulating drugs: A new frontier in the treatment of essential hypertension

Hypertension

Volumn 32, Issue 3, 1998, Pages 380-386

  Kurtz, Theodore W ^a,b   Gardner, David G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin; Blood pressure; Drugs; Genetics; Hypertension, essential; Thiazolidinediones; Transcription

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; CALCITRIOL; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; FLUTAMIDE; HYDROCORTISONE; LEVOTHYROXINE; LIGAND; RALOXIFENE; RETINOIC ACID; RETINOID; SPIRONOLACTONE; TAMOXIFEN; TRANSCRIPTION FACTOR; TROGLITAZONE; VITAMIN D;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CELL GROWTH; ESSENTIAL HYPERTENSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0031683008     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.380     Document Type: Review

References (68)

1. Page IH. The mosaic theory of arterial hypertension: its interpretation. Perspect Biol Med. 1967;10:325-333.
2. Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet. 1987;2:435-437.
3. Thurmann PA. Left ventricular and microvascular hypertrophy in essential hypertension: clinical relevance and prognostic implications. Int J Clin Pharmacol Ther. 1997;35:181-187.
4. Cai W, Hu L, Foulkes JG. Transcription-modulating drugs: mechanism and selectivity. Curr Opin Biotechnol. 1996;7:608-615.
5. Gustafsson JÅ. Raloxifene: magic bullet for heart and bone? Nat Med. 1998;4:152-153.
6. Wu DA, Bu X, Warden CH, Shen DD, Jeng CY, Sheu WH, Fuh MM, Katsuya T, Dzau VJ, Reaven GM, Lusis AJ, Rotter JI, Chen YD. Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. J Clin Invest. 1996;97:2111-2118.
7. Aitman TJ, Gotoda T, Evans AL, Imrie H, Heath KE, Trembling PM, Truman H, Wallace CA, Rahman A, Doré C, Flint J, Kren V, Zidek V, Kurtz TW, Pravenec M, Scott J. Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet. 1997;16:197-201.
8. Bouger A, Van Lith HA, Kren V, Krenova D, Bila V, Vorlicek J, Zidek V, Musilova A, Zbodinska M, Wang JM, Van Zutphen BFM, Kurtz TW, Pravenec M. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. J Clin Invest. 1996;98:856-862.
9. Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet. 1996;12:44-51.
10. Spencer CM, Markham A. Troglitazone. Drugs. 1997;54:89-101.
11. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433-439.
12. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
13. Pershadsingh HA, Benson S, Szollozi J, Hyun WC, Feuerstein BG, Kurtz TW. Effect of ciglitazone on blood pressure and intracellular calcium metabolism. Hypertension. 1993;21:1020-1023.
14. Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents. Hypertension. 1996;28:219-223.
15. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism. 1993;42:75-80.
16. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RN, Meglasson MD. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes. 1994;43:204-211.
17. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995;96:354-360.
18. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
19. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA. Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens. 1997;10:440-446.
20. Graf K, Xi XP, Hsueh WA, Law RE. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Lett. 1997;400:119-121.
21. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
22. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
23. Perlmann T, Evans RM. Nuclear receptors in Sicily: all in the famiglia. Cell. 1997;90:391-397.
24. Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
25. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37:907-925.
26. DiRenzo J, Söderström M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol. 1997;17:2166-2176.
27. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JRJ, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997;386:407-410.
28. Miano JM, Topouzis S, Majesky MW, Olson EN. Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells. Circulation. 1996;93:1886-1895.
29. Warrell RP Jr, de Th'e H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med. 1993;329:177-189.
30. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol. 1995;33:44-52.
31. Lenhard JM, Kliewer SA, Paulik MA, Plunket KD, Lehmann JM, Weiel JE. Effects of troglitazone and metformin on glucose and lipid metabolism: alterations of two distinct molecular pathways. Biochem Pharmacol. 1997;54:801-808.
32. McGarry JD. Disordered metabolism in diabetes: have we underemphasized the fat component? J Cell Biochem. 1994;55(suppl):29-38.
33. Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-α-induced inhibition of insulin signaling. J Clin Invest. 1997;100:1863-1869.
34. Adams M, Montague CT, Prins JB, Holder JCSSA, Sanders L, Digby JE, Sewter CP, Lazar MA, Chatterjee KK, O'Rahilly S. Activators of peroxisome proliferator activated receptor gamma have depot specific effects on human preadipocyte differentiation. J Clin Invest. 1997;100: 3149-3153.
35. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24:170-175.
36. 2+ currents and not endothelial nitric oxide production. Diabetes. 1997;46:659-664.
37. Itoh H, Doi K, Tanaka T, Hosoda K, Ogawa Y, Igaki T, Yamashita J, Chun T, Inoue M, Masatsugu K, Nakao K. Molecular cloning and gene expression of rat peroxisome proliferator activated receptor gamma and effect of thiazolidinediones on secretion of endothelium derived relaxing peptide: possible linkage of insulin resistance and hypertension. Hypertension. 1997;30:504. Abstract.
38. Goodfriend TL, Egan BM. Nonesterified fatty acids in the pathogenesis of hypertension: theory and evidence. Prostaglandins Leukot Essent Fatty Acids. 1997;57:57-63.
39. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230-1239.
40. Altiok S, Xu M, Spiegelman BM. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev. 1997;11:1987-1998.
41. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest. 1987;79:1706-1712.
42. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-Dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest. 1991;87: 1889-1895.
43. Li Q, Gardner DG. Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3. J Biol Chem. 1994;269: 4934-4939.
44. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest. 1996;97:1577-1588.
45. Dostal DE, Hunt RA, Kule CE, Bhat GJ, Karoor V, McWhinney CD, Baker KM. Molecular mechanisms of angiotensin II in modulating cardiac function: intracardiac effects and signal transduction pathways. J Mol Cell Cardiol. 1997;29:2893-2902.
46. Kakiki M, Morohashi K, Nomura M, Omura T, Horie T. Expression of aldosterone synthase cytochrome P450 (P450aldo) mRNA in rat adrenal glomerulosa cells by angiotensin II type 1 receptor. Endocr Res. 1997; 23:277-295.
47. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 1995;95:1353-1362.
48. Regenass S, Resink TJ, Kern F, Buhler FR, Hahn AW. Angiotensin-II-induced expression of laminin complex and laminin A-chain-related transcripts in vascular smooth muscle cells. J Vasc Res. 1994;31:163-172.
49. Ju H, Dixon IM. Effect of angiotensin II on myocardial collagen gene expression. Mol Cell Biochem. 1996;163-164:231-237.
50. Hsueh WA, Do YS, Anderson PW, Law RE. Angiotensin II in cell growth and matrix production. Adv Exp Med Biol. 1995;377:217-223.
51. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest. 1994;93:2431-2437.
52. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol. 1997;79:12-16.
53. 1 receptor subtype. Circ Res. 1993;73: 413-423.
54. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, Ogawa E, Igaki T, Yamashita J, Masuda I, Yoshimasa T, Tanaka I, Saito Y, Nakao K. Significance of ventricular myocyte and nonmyocyte interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation. 1997;96:3737-3744.
55. Liao DF, Monia B, Dean N, Berk BC. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem. 1997;272:6146-6150.
56. Zou Y, Komuro I, Yamazaki T, Aikawa R, Kudoh S, Shiojima I, Hiroi Y, Mizuno T, Yazaki Y. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271:33592-33597.
57. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 1993;73:381-393.
58. Wen Y, Scott S, Liu Y, Gonzales N, Nadler JL. Evidence that angiotensin II and lipoxygenase products activate c-Jun NH2-terminal kinase. Circ Res. 1997;81:651-655.
59. Kudoh S, Komuro I, Mizuno T, Yamazaki T, Zou Y, Shiojima I, Takekoshi N, Yazaki Y. Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res. 1997;80:139-146.
60. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76: 1025-1037.
61. Baukal AJ, Hunyady L, Can KJ, Balla T. Evidence for participation of calcineurin in potentiation of agonist-stimulated cyclic AMP formation by the calcium-mobilizing hormone, angiotensin II. J Biol Chem. 1994; 269:24546-24549.
62. Molkentin JD, Lu J-R, Amos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215-228.
63. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature. 1995;375:247-250.
64. Griffin KA, Picken M, Bidani AK. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int. 1994;46:1010-1018.
65. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071.
66. Libby P, Ganz P. Restenosis revisited: new targets, new therapies. N Engl J Med. 1997;337:418-419.
67. Darnell JEJ. STATs and gene regulation. Science. 1997;277:1630-1635.
68. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science. 1998;279:703-707.